Late treatment study
et al., Science China Life Sciences, 2020 May 15, 1-7, doi:10.1007/s11427-020-1732-2 (Peer Reviewed)
Low Dose of Hydroxych loroquine Reduces Fatality of Critically Ill Patients With COVID-19
Retrospective, 550 critically ill patients. 19% fatality for HC
Q versus 47% for non-HC
Q, RR 0.395, p
The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 pg/mL to 5.2 pg/mL (p
<0.05) at the end of the treatment in the HC
Q group but there was no change in the control group.
death, ↓60.5%, p=0.002
Please send us corrections, updates, or comments.